{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:16:13Z","timestamp":1760548573096,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100016372","name":"Desitin Arzneimittel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016372","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ejpb.2020.12.007","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T22:16:38Z","timestamp":1608156998000},"page":"365-370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Determination of healthcare resource and cost implications of using alternative sodium valproate formulations in the treatment of epilepsy in children in England: A retrospective database review"],"prefix":"10.1016","volume":"158","author":[{"given":"Hannah","family":"Batchelor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejpb.2020.12.007_b0005","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1542\/peds.2010-1371","article-title":"A national profile of childhood epilepsy and seizure disorder","volume":"129","author":"Russ","year":"2012","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.ejpb.2020.12.007_b0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmjpo-2017-000088","article-title":"Anti-epileptic drug utilisation in paediatrics: a systematic review","volume":"1","author":"Egunsola","year":"2017","journal-title":"BMJ Paediatrics Open"},{"issue":"7","key":"10.1016\/j.ejpb.2020.12.007_b0015","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.seizure.2006.06.003","article-title":"Adherence to treatment in patients with epilepsy: associations with seizure control and illness beliefs","volume":"15","author":"Jones","year":"2006","journal-title":"Seizure"},{"issue":"5","key":"10.1016\/j.ejpb.2020.12.007_b0020","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/dmcn.12942","article-title":"Adherence to antiepileptic drugs in children with epilepsy in a Scottish population cohort","volume":"58","author":"Shetty","year":"2016","journal-title":"Dev. Med. Child Neurol."},{"issue":"6","key":"10.1016\/j.ejpb.2020.12.007_b0025","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0149-2918(99)80026-5","article-title":"Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice","volume":"21","author":"Farmer","year":"1999","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejpb.2020.12.007_b0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.yebeh.2018.01.031","article-title":"Adherence barriers in pediatric epilepsy: From toddlers to young adults","volume":"80","author":"Gutierrez-Colina","year":"2018","journal-title":"Epilepsy Behav."},{"issue":"4 PART 1","key":"10.1016\/j.ejpb.2020.12.007_b0035","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0022-3476(05)82496-5","article-title":"Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance, and preference","volume":"120","author":"Cloyd","year":"1992","journal-title":"J. Pediatrics"},{"issue":"10","key":"10.1016\/j.ejpb.2020.12.007_b0040","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.arcped.2005.07.009","article-title":"Acceptabilit\u00e9 et tol\u00e9rance du valproate de sodium, granules \u00e0 lib\u00e9ration prolong\u00e9e, en monoth\u00e9rapie chez l'enfant \u00e9pileptique \u00e0 partir de trois ans","volume":"12","author":"Motte","year":"2005","journal-title":"Archives de P\u00e9diatrie"},{"issue":"03","key":"10.1016\/j.ejpb.2020.12.007_b0045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2007-1017619","article-title":"Epilepsietherapie mit retardierter Valproins\u00e4ure - Erfahrungen mit 1172 Patienten","volume":"26","author":"Bergmann","year":"1999","journal-title":"Akt Neurol"},{"key":"10.1016\/j.ejpb.2020.12.007_b0050","unstructured":"N. England, National Tariff Payment System. https:\/\/www.gov.uk\/government\/publications\/national-tariff-payment-system-2014-to-2015, 2014-2015."},{"key":"10.1016\/j.ejpb.2020.12.007_b0055","unstructured":"L. Curtis, Unit Costs of Health and Social Care 2014. Personal Social Services Research Unit, University of Kent, Canterbury, 2014. https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/unit-costs-2014\/?file=full."},{"key":"10.1016\/j.ejpb.2020.12.007_b0060","unstructured":"Wales, N.E.a., Electronic Drug Tariff. http:\/\/www.ppa.org.uk\/edt\/September_2014\/mindex.htm, 2014."},{"key":"10.1016\/j.ejpb.2020.12.007_b0065","unstructured":"EMA, Draft Guideline on Pharmaceutical Development of Medicines for Paediatric Use EMA\/CHMP\/QWP\/180157\/2011 2011. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-pharmaceutical-development-medicines-paediatric-use_en-0.pdf."},{"issue":"6","key":"10.1016\/j.ejpb.2020.12.007_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098348","article-title":"Oral medicines for children in the European paediatric investigation plans","volume":"9","author":"van Riet-Nales","year":"2014","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.ejpb.2020.12.007_b0075","article-title":"Impact of sample size and variability on the power and type I error rates of equivalence tests: a simulation study","volume":"19","author":"Rusticus","year":"2014","journal-title":"Pract. Assess., Res., Evaluat."},{"issue":"6","key":"10.1016\/j.ejpb.2020.12.007_b0080","first-page":"795","article-title":"Factors influencing prescribing decisions of physicians: a review","volume":"28","author":"Davari","year":"2018","journal-title":"Ethiopian J. Health Sci."},{"key":"10.1016\/j.ejpb.2020.12.007_b0085","unstructured":"P.F. Committee, BNF for Children (online). London: BMJ Group, Pharmaceutical Press, and RCPCH Publications. <http:\/\/www.medicinescomplete.com> [Accessed on [20-10-2020]]."},{"issue":"2","key":"10.1016\/j.ejpb.2020.12.007_b0090","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.pediatrneurol.2008.09.021","article-title":"First-drug treatment failures in children newly diagnosed with epilepsy","volume":"40","author":"Dudley","year":"2009","journal-title":"Pediatr. Neurol."},{"issue":"6","key":"10.1016\/j.ejpb.2020.12.007_b0095","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s00415-009-5062-1","article-title":"Pregnancy and epilepsy: what should we tell our patients?","volume":"256","author":"Tomson","year":"2009","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.ejpb.2020.12.007_b0100","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/cpdd.118","article-title":"Pharmacokinetics of rabeprazole granules versus tablets, and the effect of food on the pharmacokinetics of rabeprazole granules in healthy adults\u2014cross-study comparison","volume":"3","author":"Thyssen","year":"2014","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"3","key":"10.1016\/j.ejpb.2020.12.007_b0105","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4103\/2231-4040.85539","article-title":"Rabeprazole sodium delayed-release multiparticulates: Effect of enteric coating layers on product performance","volume":"2","author":"Tirpude","year":"2011","journal-title":"J. Adv. Pharm. Technol. Res."},{"issue":"1","key":"10.1016\/j.ejpb.2020.12.007_b0110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijpharm.2010.04.048","article-title":"Specific aspects of gastro-intestinal transit in children for drug delivery design","volume":"395","author":"Bowles","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.12.007_b0115","doi-asserted-by":"crossref","unstructured":"H.K. Batchelor et al., Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients. Europ. J. Pharm. Biopharm. 85(3, Part B) (2013) 833-842.","DOI":"10.1016\/j.ejpb.2013.04.015"},{"key":"10.1016\/j.ejpb.2020.12.007_b0120","unstructured":"Sanofi, Epilim Chrono 300mg Controlled Release Tablets. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/3987\/smpc#gref (accessed 20-10-20)."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2020.12.007_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2015.02.068","article-title":"Can preschool-aged children swallow several minitablets at a time? Results from a clinical pilot study","volume":"485","author":"Kluk","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.ejpb.2020.12.007_b0130","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1136\/gut.27.8.886","article-title":"Transit of pharmaceutical dosage forms through the small intestine","volume":"27","author":"Davis","year":"1986","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.ejpb.2020.12.007_b0135","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1211\/jpp.59.7.0005","article-title":"Gastrointestinal transit of model mini-tablet controlled release oral dosage forms in fasted human volunteers","volume":"59","author":"Podczeck","year":"2007","journal-title":"J. Pharm. Pharmacol."},{"issue":"11","key":"10.1016\/j.ejpb.2020.12.007_b0140","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1055\/s-2004-830299","article-title":"Valproate sustained release in the treatment of epilepsy","volume":"73","author":"Stefan","year":"2005","journal-title":"Fortschr. Neurol. Psychiatr."},{"key":"10.1016\/j.ejpb.2020.12.007_b0145","unstructured":"EMA, Guideline on quality of modified release products. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-quality-oral-modified-release-products_en.pdf, 2014."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641120303659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641120303659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:45:10Z","timestamp":1760546710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641120303659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":29,"alternative-id":["S0939641120303659"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2020.12.007","relation":{},"ISSN":["0939-6411"],"issn-type":[{"type":"print","value":"0939-6411"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of healthcare resource and cost implications of using alternative sodium valproate formulations in the treatment of epilepsy in children in England: A retrospective database review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2020.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}